Benzinga | Aug 6, 2020 05:36PM EDT

Nektar Therapeutics Q2 EPS $(0.45) Beats $(0.68) Estimate, Sales $48.40M My Not Compare To $22.80M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.68) by 33.82 percent. This is a 28.57 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $48.40 million which beat the analyst consensus estimate of $22.80 million by 112.28 percent. This is a 107.59 percent increase over sales of $23.32 million the same period last year.